Bio-Techne (TECH) Cash & Equivalents (2009 - 2026)

Bio-Techne's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $209.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 49.16% year-over-year to $209.8 million; the TTM figure through Mar 2026 stood at $209.8 million (up 49.16% YoY), while the FY2025 annual figure was $162.2 million, up 6.85% from the prior year.
• Cash & Equivalents was $209.8 million for Q1 2026 at Bio-Techne, up from $172.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $209.8 million in Q1 2026 to a low of $127.3 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $161.0 million across 5 years, with a median of $162.2 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents retreated 22.7% in 2025, then surged 49.16% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $164.7 million in 2022, then declined by 20.98% to $130.1 million in 2023, then surged by 36.44% to $177.5 million in 2024, then dropped by 2.63% to $172.9 million in 2025, then gained by 21.37% to $209.8 million in 2026.
• The last three Cash & Equivalents figures came in at $209.8 million (Q1 2026), $172.9 million (Q4 2025), and $145.0 million (Q3 2025), per Business Quant data.